臺灣博碩士論文加值系統

高壓氧治療可以提高組織內氧氣濃度並改善敗血症中低血壓和代謝性酸中毒的情形，而且高壓氧治療還可以對於免疫系統在不同情況下產生抑制或加強的效果。本實驗設計以腹腔內注射內毒素(lipopolysaccharide, LPS)12.5mg/kg誘發小鼠產生全身性發炎反應症候群(systemic inflammatory response syndrome , SIRS)之後，給予即時的高壓氧治療(2ATA,75分鐘)來評估高壓氧治療於內毒素誘發小鼠全身性發炎反應症候群的情形下對其存活率的影響與效果，並且佐以其對細胞素的抑制或促進效果來推究其可能之作用機轉。此外，多重器官衰竭是敗血病最終死亡的重要原因，而肝臟衰竭又為其最重要之指標。所以本實驗也同時觀察高壓氧治療對於內毒素誘發小鼠全身性發炎反應症候群時肝臟的保護效果。實驗結果如下：一、於注射內毒素後即刻給予高壓氧治療(2ATA,75分鐘)可以將內毒素誘發小鼠全身性發炎反應症候群的死亡率由75%下降到25%，而且可以明顯降低腫瘤壞死因子(tumor necrosis factor-α,TNF-α)的濃度，同時也相對的可以明顯提高介白素-10(Interleukin-10, IL-10)的濃度；另外也有保護肝臟免於急性大量壞死的作用。以上結果顯示，早期即時的高壓氧治療對於內毒素誘發小鼠全身性發炎反應症候群具有療效，同時可保護肝臟免於急性衰竭。其效果可能來自於高壓氧氣降低與調節發炎反應的調控。

The present study is designed to reveal the possible mechanism and the therapeutic potential for hyperbaric oxygen therapy (HBO) in the treatment of sepsis , also protection effect on liver during sepsis. Immediate HBO treatment ( 2 ATA , 75 min ) was applied to assess the survival rate of septic BALB/c mice induced by LPS within 84 hours period. The changes of plasma TNF-α and IL-10 after LPS challenge were measured. The pathological change of liver at 24 hours after LPS challenge treated with/without HBO treatment were also studied. The experimental results demonstrates that: (1) immediate HBO exposure after LPS challenge increases the survival rate of mice from 25% to 75%, (2) the plasma concentration of TNF-α after LPS challenge is reduced by immediate HBO treatment, (3) HBO treatment may protect liver from septic injury. In conclusion , HBO treatment exerts beneficial effects on sepsis induced by LPS in BALB/c mouse. The possible mechanism may be due to immunomodulation effect of HBO on immune system.

目錄
目錄 I
圖次 II
中文摘要 III
英文摘要 IV
第一章 緒言 1
第二章 研究方法與材料 16
第三章 結果 23
第四章 討論 28
第五章 結論 33
第六章 參考文獻 42
圖次
圖一、高壓氧對於注射內毒素LPS之小鼠在84小時內存活率的影響34
圖二、不同組別小鼠血漿中TNF-α濃度變化的情形 35
圖三、不同組別小鼠血漿中IL-10濃度變化的情形 36
圖四、不同組別小鼠血漿中GOT濃度變化的情形 37
圖五、不同組別小鼠血漿中GPT濃度變化的情形 38
圖六、嚴重感染病患臨床表現症狀與相對應發炎指標時間病程圖 39
圖七、Liver pathology at 24 hrs after LPS injection (Low power) 40
圖八、Liver pathology at 24 hrs after LPS injection (High power) 41

Aono K, Isobe K, Kiuchi K, Fan ZH, Ito M, Takeuchi A, Miyachi M, Nakashima I, Nimura Y: In vitro and in vivo expression of inducible nitric oxide synthase during experimental endotoxemia: involvement of other cytokines. J Cell Biochem. 1997;65:349-58.

Ayala A, Chaudry IH: Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock. 1996;6:S27-38.

Barron RL: Pathophysiology of septic shock and implications for therapy. Clin Pharm. 1993;12(11):829-45.

Barton R, Cerra FB: The hypermetabolism. Multiple organ failure syndrome. Chest. 1989;9:1153-60.

Blackwell TS, Christman JW: Sepsis and cytokines: current status. Br J Anaesth. 1996;77:110-7.

Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-72.

Buras JA, Stahl GL, Svoboda KKH, and Reenstra WR: Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol. 2000;278:292-302.

Caruana JA Jr, Montes M, Camara DS, Ummer A, Potmesil SH, Gage AA: Functional and histopathologic changes in the liver during sepsis. Surg Gynecol Obstet. 1982;154:653-6.

Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-51.

Cross AS, Opal SM: A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med. 2003;138:502-5.

Cuzzocrea S, Imperatore F, Costantino G, Luongo C, Mazzon E, Scafuro MA, Mangoni G, Caputi AP, Rossi F, Filippelli A: Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat. Shock. 2000;13:197-203.

Deitch EA: Multiple organ failure. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992;216:117-34.

Dennis LK, Eugene B, Anthony SF, Stephen LH, Dan LL, Jameson JL, and Kurt J: Isselbacher, Eds.Harrison''s Principles of Internal Medicine, 16th Edition

Farghali H, Canova N, Kucera T, Martinek J, Masek K: Nitric oxide synthase inhibitors modulate lipopolysaccharide-induced hepatocyte injury: dissociation between in vivo and in vitro effects. Int Immunopharmacol. 2003;3:1627-38.

Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081-95.

Fry DE, Pearlstein L, Fulton RL, Polk HC Jr: Multiple system organ failure. The role of uncontrolled infection. Arch Surg. 1980;115:136-40.

Glauser MP, Heumann D, Baumgartner JD, Cohen J: Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis. 1994;18:S205-16.

Haapaniemi T, Nylander G, Sirsjo A, Larsson J: Hyperbaric oxygen reduces ischemia-induced skeletal muscle injury. Plast Reconstr Surg. 1996;97:602-7.

Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269-77.

Hampson NB: Hyperbaric oxygen: a plea for uniform nomenclature. Undersea Hyperb Med. 1999;26:267.

Harbrecht BG, Stadler J, Demetris AJ, Simmons RL, Billiar TR: Nitric oxide and prostaglandins interact to prevent hepatic damage during murine endotoxemia. Am J Physiol. 1994;266:G1004-10.

Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Shires GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-53.

Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RR, Rodenburg RJ: Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res. 2004;5:93-9.

Kariakin AM, Kucher VV: The pathogenesis of sepsis and the possibilities for its treatment using nondrug methods. Vestn Khir Im I I Grek. 1995;154:9-12.

Kumins NH, Hunt J, Gamelli RL, Filkins JP: Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats. Shock. 1996;5:385-8.

Lahat N. Bitterman H. Yaniv N. Kinarty A. Bitterman N: Exposure to hyperbaric oxygen induces tumour necrosis factor-alpha (TNF-alpha) secretion from rat macrophages. Clin Exp Immunol. 1995;102:655-9.

Laskin DL, Heck DE, Gardner CR, Feder LS, Laskin JD: Distinct patterns of nitric oxide production in hepatic macrophages and endothelial cells following acute exposure of rats to endotoxin. J Leukoc Biol. 1994;56:751-8.

Lin HC, Wan FJ, Wu CC, Tung CS, Wu TH: Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol. 2005;508:249-54.

Luongo C, Imperatore F, Cuzzocrea S, Filippelli A, Scafuro MA, Mangoni G, Portolano F, Rossi F: Effects of hyperbaric oxygen exposure on a zymosan-induced shock model. Crit Care Med. 1998;26:1972-6.

Lynn WA, Cohen J: Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis. 1995;20:143-58.

Maestroni GJ: Melatonin as a therapeutic agent in experimental endotoxic shock. J Pineal Res. 1996;20:84-9.

Martin C, Saux P, Mege JL, Perrin G, Papazian L, Gouin F: Prognostic values of serum cytokines in septic shock. Intensive Care Med. 1994;20:272-7.

Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC: Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996;40:501-10.

Nadel S: Helping to understand studies examining genetic susceptibility to sepsis. Clin Exp Immunol. 2002;127:191-2.

Pedoto A, Nandi J, Yang ZJ, Wang J, Bosco G, Oler A, Hakim TS, Camporesi EM: Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in rats. Clin Exp Pharmacol Physiol. 2003;30:482-8.

Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-23.

Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW: Interleukin-10 protects against lethality of intra-abdominal infection and sepsis. J Gastrointest Surg. 2000;4:70-76.

Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL Jr, Platt R: Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997;278:234-40.

Scott MJ, Godshall CJ, Cheadle WG: Jaks, STATs, Cytokines, and Sepsis. Clin Diagn Lab Immunol. 2002;9:1153-9.
Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, et al.: Tumour necrosis factor in man: clinical and biological observations. Br J Cancer. 1987;56:803-8.

Sewerynek E, Melchiorri D, Reiter RJ, Ortiz GG, Lewinski A: Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol. 1995;293:327-34.

Shea LM, Beehler C, Schwartz M, Shenkar R, Tuder R, Abraham E: Hyperoxia activates NF-kappaB and increases TNF-alpha and IFN-gamma gene expression in mouse pulmonary lymphocytes. J Immunol. 1996;157:3902-8.

Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd, Kufe DW: Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344-50.

Slotman GJ: Hyperbaric oxygen in systemic inflammation ... HBO is not just a movie channel anymore. Crit Care Med. 1998;26:1932-3.

Stone R: Search for sepsis drugs goes on despite past failures. Science. 1994;264:365-7.

Thom SR, Lauermann MW, Hart GB: Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. J Infect Dis. 1986;154:504-10.

Tracey KJ: The acute and chronic pathophysiologic effects of TNF : mediation of septic shock and wasting (cachexia). In Tumor Necrosis Factors : The Molecules and their Emerging role in Medicine (Beutler B., ed) pp255-273, Raven, New York

Uwagawa T, Unemura Y, Yamazaki Y: Hyperbaric oxygenation after portal vein emobilization for regeneration of the predicted remnant liver. J Surg Res. 2001;100:63-8.

Van Bossuyt H, De Zanger RB, Wisse E: Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol. 1988;7:325-37.

Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun. 1996;64:4733-8.

Wang JH, Redmond HP, Watson RW, Bouchier-Hayes D : Role of lipopolysaccharide and tumor necrosis factor-alpha in induction of hepatocyte necrosis. Am J Physiol. 1995;269:G297-304.

Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med. 1999;340:207-14.

Yamada T, Taguchi T, Hirata Y, Toyohara T, Hirose R, Suita S, Yagi H: The effect of hyperbaric oxygenation on ischemia-reperfusion injury of the small intestine. Transplant Proc. 1994;26:1506-7.

Yamashita M, Yamashita M: Hyperbaric oxygen treatment attenuates cytokine induction after massive hemorrhage. Am J Physiol Endocrinol Metab. 2000;278:E811-6.

Yang ZJ, Bosco G, Montante A, Ou XI, Camporesi EM: Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-alpha production and lung neutrophil sequestration. Eur J Appl Physiol. 2001;85:96-103.

Yasar M, Yildiz S, Mas R, Dundar K, Yildirim A, Korkmaz A, Akay C, Kaymakcioglu N, Ozisik T, Sen D: The effect of hyperbaric oxygen treatment on oxidative stress in experimental acute necrotizing pancreatitis. Physiol Res. 2003;52:111-6.

Zamboni WA, Wong HP, Stephenson LL: Effect of hyperbaric oxygen on neutrophil concentration and pulmonary sequestration in reperfusion injury. Arch Surg. 1996;131:756-60.

Zhidkov KP, Klechikov VZ, Bogatyr'' MN: [Experience in the treatment of severe forms of sepsis by extracorporeal therapy and hyperbaric oxygenation] Anesteziol Reanimatol. 1997;3:49-51.